查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438129

到 2030 年泌尿道治疗市场预测：按类型、治疗类型、诊断、最终用户和地区进行的全球分析

Uropathy Treatment Market Forecasts to 2030 - Global Analysis By Type (Obstructive Uropathy, Functional Uropathy, Inflammatory Uropathy, Congenital Uropathy and Urological Cancers), Treatment Type, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球泌尿道疾病治疗市场规模为 44 亿美元，预计到 2030 年将达到 66 亿美元，预测期内复合年增长率为 6.0%。

泌尿道疾病是指影响泌尿道的多种疾病，包括肾臟、输尿管、膀胱和尿道。泌尿道疾病的治疗取决于根本原因和严重程度。透过 3D 前列腺 MRI 等先进影像技术进行早期诊断可以及时进行干预。个人化医疗根据个人的遗传和分子特征量身定制治疗计划，为更有效、更有针对性的治疗铺平道路。

根据发表在《泌尿学进展》杂誌上的一项研究，肾结石影响着世界上大约15% 的人口，儘管它影响所有年龄层的人，但在20 至49 岁之间，男性比女性更常见。泌尿系统疾病频繁发生且呈上升趋势。

泌尿系统疾病发生率增加

随着尿道感染、肾结石和摄护腺疾病的盛行率持续上升，对有效和创新治疗方法的需求不断增长。患者数量的快速增加不仅凸显了对先进治疗解决方案的迫切需求，也推动了泌尿系统治疗领域的研发力度。因此，在意识和教育提高的推动下，人们对泌尿系统健康的兴趣日益浓厚，将进一步加速市场扩大，增加对诊断、药物和药物的需求，以满足泌尿系统疾病相关不断增长的医疗需求，为医疗进步创造机会。干预措施。

缺乏合格的医疗专业人员

泌尿道疾病是非常规治疗方法，需要专门的知识和专业知识来进行正确的管理和监测。缺乏合格的专业人员，包括泌尿系统和接受过泌尿系统疾病特殊培训的医疗保健提供者，会导致诊断延迟、治疗不足和患者照护不佳。此外，短缺可能会导致现有医疗保健专业人员的工作量增加，导致倦怠和护理品质不佳，从而阻碍市场成长。

提高泌尿系统健康意识和各种治疗方案的可用性

随着人们对泌尿系统疾病及其潜在后果的了解越来越多，人们越来越重视预防措施和早期发现。这一趋势推动了患者检查、咨询和积极就医行为的激增，对泌尿系统护理的需求产生了积极影响。这不仅满足了个人偏好，还促进了个人化治疗计划并提高了患者的整体满意度和依从性。意识的提高和治疗方案的综合效应正在促进市场成长。

缺乏标准化通讯协定和指南

泌尿道疾病治疗缺乏既定标准，导致治疗程序、剂量和使用方法存在差异，引发了人们对安全性、有效性和可重复性的担忧。这些矛盾为医疗专业人员带来了不确定性，并不愿意将泌尿道疾病纳入日常临床实务。由于缺乏标准化和安全保证，患者可能不愿意考虑泌尿道疾病的治疗。标准化通讯协定的开发和推广对于克服这些障碍和增强市场信心至关重要。

COVID-19 的影响

加上封锁和旅行限制，医疗保健系统和资源面临前所未有的压力，导致泌尿系统手术延迟，并减少了因非紧急情况就诊的患者。许多医疗机构已将重点和资源转向应对 COVID-19 病例激增，从而影响了泌尿系统护理的提供。此外，大流行的经济影响影响了患者的优先事项，有些人出于财务考虑而选择推迟选择性泌尿系统治疗，从而阻碍了市场成长。

在预测期内，阻塞性尿路疾病领域预计将是最大的。

阻塞性尿路疾病领域预计将出现良好的增长，因为阻塞性尿路疾病患者的尿流不畅，可能导致各种併发症，如肾臟损伤和感染疾病。Masu。泌尿系统疾病治疗市场对解决阻塞性泌尿系统疾病的干预措施（例如外科手术、导管插入术和药物治疗）的需求可能会增加。此外，专注于解决阻塞性泌尿道疾病根本原因的研发可能会激增，包括开发标靶治疗以推动市场成长。

尿液检查领域预计在预测期内复合年增长率最高

尿液检查领域预计在预测期内复合年增长率最高。这是因为，尿液样本的分析可以让医疗专业人员检测到各种异常情况，例如感染疾病、肾臟疾病、代谢紊乱等，这些异常情况可能会影响泌尿系统疾病的治疗过程。准确的尿液检查结果有助于诊断泌尿系统疾病的根本原因，并制定个人化且有效的治疗计画。此外，尿液检查有助于监测和评估治疗效果，并允许根据患者反应进行调整，从而促进市场成长。

占比最大的地区：

由于肾结石、前列腺肥大和尿失禁等泌尿系统疾病的高发生率，推动了对治疗方案的需求，预计亚太地区在预测期内将占据最大的市场占有率。此外，微创手术、机器人辅助手术和先进的影像技术正在改变泌尿系统医学，提供准确有效的治疗和更快的恢復时间，推动该地区的市场成长。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。这是因为肾结石、尿道感染(UTI) 和前列腺癌等疾病在北美变得越来越常见。这是由于人口老化、久坐的生活方式和肥胖率上升等因素所造成的。此外，泌尿系统领域近年来取得了重大进展，包括微创手术、机器人手术和个人化医疗方法的发展。这些进步正在改善患者的治疗效果并缩短復原时间，从而推动市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球尿路疾病治疗市场：依类型

  • 阻塞性泌尿道疾病
  • 功能性泌尿道疾病
  • 发炎泌尿道疾病
  • 先天性泌尿系统疾病
  • 泌尿系统癌症

第六章全球泌尿道疾病治疗市场：依治疗类型

  • 药物治疗
    • 抗生素
    • 止痛药
    • α阻断剂或α还原酶抑制剂
    • 荷尔蒙疗法
  • 外科手术
    • 膀胱镜
    • 碎石术
    • 输尿管镜
    • 支架置入
  • 生活方式改变

第七章全球泌尿道疾病治疗市场：依诊断分类

  • 尿液检查
  • 验血
  • 影像检查

第八章全球泌尿道疾病治疗市场：依最终用户分类

  • 医院和诊所
  • 门诊手术中心
  • 其他的

第九章全球泌尿道疾病治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbott
  • Novartis AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Antares Pharma
  • Allergan
  • AstraZeneca
  • Cook Medical
  • Sanofi
  • Olympus Corporation
  • Teleflex Incorporated
  • Argon Medical Devices, Inc
Product Code: SMRC25098

According to Stratistics MRC, the Global Uropathy Treatment Market is accounted for $4.4 billion in 2023 and is expected to reach $6.6 billion by 2030 growing at a CAGR of 6.0% during the forecast period. Uropathy refers to a broad range of conditions affecting the urinary tract, including the kidneys, ureters, bladder, and urethra. Treatment for uropathy depends on the specific underlying cause and severity of the condition. Innovation extends beyond procedures. Early diagnosis through advanced imaging techniques like 3D prostate MRI empowers timely intervention. Personalized medicine tailors treatment plans based on individual genetic and molecular profiles, paving the way for more effective and targeted therapies.

According to a study published in Advances in Urology, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20-49 years.

Market Dynamics:

Driver:

Rising incidence of urological conditions

As the prevalence of disorders such as urinary tract infections, kidney stones, and prostate issues continues to rise, there is a heightened demand for effective and innovative treatments. This surge in patient numbers not only underscores the urgent need for advanced therapeutic solutions but also propels research and development efforts within the Uropathy Treatment sector. Thus the increased focus on urological health, fuelled by the rise in awareness and education, further amplifies the market's expansion, creating opportunities for advancements in diagnostics, pharmaceuticals, and medical interventions to cater to the escalating healthcare needs associated with urological conditions.

Restraint:

Shortage of qualified healthcare professionals

Uropathy, as an unconventional treatment, requires specialized knowledge and expertise for proper administration and monitoring. The scarcity of qualified professionals including urologists and healthcare providers with specific training in uropathy, results in delayed diagnosis, inadequate treatment, and compromised patient care. Moreover, the shortage contributes to increased workloads for existing healthcare professionals, potentially leading to burnout and decreased quality of care impeding the market growth.

Opportunity:

Increased awareness of urological health and the availability of various treatment options

As individuals become more informed about urological disorders and their potential consequences, there is a growing emphasis on preventive measures and early detection. This trend has driven a surge in patient screenings, consultations, and proactive healthcare seeking behaviours, positively influencing the demand for uropathy treatments. This not only caters to individual preferences but also promotes personalized treatment plans, enhancing overall patient satisfaction and compliance. The combined effect of heightened awareness and treatment options contributes to the growth of the market

Threat:

Lack of standardized protocols and guidelines

The lack of established norms for uropathy treatments leads to variability in procedures, dosages, and application methods, raising concerns about safety, efficacy, and reproducibility. This inconsistency creates uncertainty among healthcare professionals, making them hesitant to integrate uropathy into routine clinical practices. Patients may be hesitant to explore uropathy treatments due to the perceived lack of standardization and assurance of safety. Developing and promoting standardized protocols are essential for overcoming these obstacles and fostering confidence in the market.

Covid-19 Impact

The unprecedented strain on healthcare systems and resources, coupled with lockdowns and travel restrictions, has led to delays in urological procedures and reduced patient visits for non-emergent conditions. Many healthcare facilities have diverted their focus and resources toward managing the surge in COVID-19 cases, affecting the delivery of uropathy treatments. Moreover, the economic repercussions of the pandemic have influenced patient priorities, with some individuals opting to postpone elective urological treatments due to financial uncertainties hampering the market growth.

The obstructive uropathy segment is expected to be the largest during the forecast period

The obstructive uropathy segment is estimated to have a lucrative growth, as patients with obstructive uropathy may experience impaired urinary flow, leading to various complications such as kidney damage and infections. The market for uropathy treatment may see an increased demand for interventions addressing obstructive uropathy, including surgical procedures, catheterization, and pharmacological treatments. Additionally, the market may witness a surge in research and development efforts focused on addressing the underlying causes of obstructive uropathy, including the development of targeted therapies which encourage in the market growth.

The urinalysis segment is expected to have the highest CAGR during the forecast period

The urinalysis segment is anticipated to witness the highest CAGR growth during the forecast period, because the analysis of urine samples allows healthcare professionals to detect various abnormalities, such as infections, kidney diseases, and metabolic disorders, influencing the course of uropathy treatments. Precise urinalysis results aid in diagnosing the root cause of urological conditions, enabling personalized and effective treatment plans. Furthermore, urinalysis contributes to the monitoring and assessment of treatment efficacy, allowing adjustments based on patient responses boosting the markets growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of urological conditions like kidney stones, prostate enlargement, and urinary incontinence increases in this region are fuelling demand for treatment options. Moreover minimally invasive surgeries, robotic-assisted procedures, and advanced imaging technologies are transforming urological care, offering precise and effective treatments with faster recovery times are driving the growth of the market in this region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to Conditions like kidney stones, urinary tract infections (UTIs), and prostate cancer are becoming increasingly common in North America. This is due to factors like aging population, sedentary lifestyles, and rising obesity rates. Moreover, the field of urology has seen significant advancements in recent years, with the development of minimally invasive procedures, robotic surgery, and personalized medicine approaches. These advancements are leading to improved patient outcomes and shorter recovery times thus encouraging the growth of the market.

Key players in the market

Some of the key players in the Uropathy Treatment Market include Abbott, Novartis AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co. Inc., GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Antares Pharma, Allergan, AstraZeneca, Cook Medical, Sanofi, Olympus Corporation, Teleflex Incorporated and Argon Medical Devices, Inc

Key Developments:

In January 2024, Abbott announced the first global procedures have been conducted using the company's new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

In January 2024, Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. FDA approval of the company's second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond

In October 2023, Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers. Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

Types Covered:

  • Obstructive Uropathy
  • Functional Uropathy
  • Inflammatory Uropathy
  • Congenital Uropathy
  • Urological Cancers

Treatment Types Covered:

  • Drug Therapy
  • Surgery Procedures
  • Lifestyle Modification

Diagnosis Covered:

  • Urinalysis
  • Blood Tests
  • Imaging Tests

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Surgical Centre
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Uropathy Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Obstructive Uropathy
  • 5.3 Functional Uropathy
  • 5.4 Inflammatory Uropathy
  • 5.5 Congenital Uropathy
  • 5.6 Urological Cancers

6 Global Uropathy Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Drug Therapy
    • 6.2.1 Antibiotics
    • 6.2.2 Pain Relievers
    • 6.2.3 Alpha-Blockers or Alpha-Reductase Inhibitors
    • 6.3.4 Hormone Therapy
  • 6.3 Surgery Procedures
    • 6.3.1 Cystoscopy
    • 6.3.2 Lithotripsy
    • 6.3.3 Ureteroscopy
    • 6.3.4 Stenting
  • 6.4 Lifestyle Modification

7 Global Uropathy Treatment Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Urinalysis
  • 7.3 Blood Tests
  • 7.4 Imaging Tests

8 Global Uropathy Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Ambulatory Surgical Centre
  • 8.4 Other End Users

9 Global Uropathy Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Novartis AG
  • 11.3 Bristol-Myers Squibb Co.
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Genentech, Inc.
  • 11.6 Eli Lilly and Company
  • 11.7 Ionis Pharmaceuticals, Inc.
  • 11.8 Pfizer, Inc.
  • 11.9 Merck & Co. Inc.
  • 11.10 GlaxoSmithKline
  • 11.11 Teva Pharmaceutical Industries Ltd.
  • 11.12 Bayer AG
  • 11.13 Antares Pharma
  • 11.14 Allergan
  • 11.15 AstraZeneca
  • 11.16 Cook Medical
  • 11.17 Sanofi
  • 11.18 Olympus Corporation
  • 11.19 Teleflex Incorporated
  • 11.20 Argon Medical Devices, Inc

List of Tables

  • Table 1 Global Uropathy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Uropathy Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Uropathy Treatment Market Outlook, By Obstructive Uropathy (2021-2030) ($MN)
  • Table 4 Global Uropathy Treatment Market Outlook, By Functional Uropathy (2021-2030) ($MN)
  • Table 5 Global Uropathy Treatment Market Outlook, By Inflammatory Uropathy (2021-2030) ($MN)
  • Table 6 Global Uropathy Treatment Market Outlook, By Congenital Uropathy (2021-2030) ($MN)
  • Table 7 Global Uropathy Treatment Market Outlook, By Urological Cancers (2021-2030) ($MN)
  • Table 8 Global Uropathy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 9 Global Uropathy Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 10 Global Uropathy Treatment Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 11 Global Uropathy Treatment Market Outlook, By Pain Relievers (2021-2030) ($MN)
  • Table 12 Global Uropathy Treatment Market Outlook, By Alpha-Blockers or Alpha-Reductase Inhibitors (2021-2030) ($MN)
  • Table 13 Global Uropathy Treatment Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 14 Global Uropathy Treatment Market Outlook, By Surgery Procedures (2021-2030) ($MN)
  • Table 15 Global Uropathy Treatment Market Outlook, By Cystoscopy (2021-2030) ($MN)
  • Table 16 Global Uropathy Treatment Market Outlook, By Lithotripsy (2021-2030) ($MN)
  • Table 17 Global Uropathy Treatment Market Outlook, By Ureteroscopy (2021-2030) ($MN)
  • Table 18 Global Uropathy Treatment Market Outlook, By Stenting (2021-2030) ($MN)
  • Table 19 Global Uropathy Treatment Market Outlook, By Lifestyle Modification (2021-2030) ($MN)
  • Table 20 Global Uropathy Treatment Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Uropathy Treatment Market Outlook, By Urinalysis (2021-2030) ($MN)
  • Table 22 Global Uropathy Treatment Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 23 Global Uropathy Treatment Market Outlook, By Imaging Tests (2021-2030) ($MN)
  • Table 24 Global Uropathy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Uropathy Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 26 Global Uropathy Treatment Market Outlook, By Ambulatory Surgical Centre (2021-2030) ($MN)
  • Table 27 Global Uropathy Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.